Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review
Open Access
- 1 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 112 (5) , 443-465
Abstract
Background: As new targeted oral antineoplastic therapies have emerged in recent years, the development of effective strategies that promote optimal adherence to cancer medication regimens has become an important priority. Methods: We conducted a scoping literature review to search for English language articles published through July 15, 2019, to identify studies that reported the testing and/or evaluation of interventions to improve adherence to oral antineoplastic agents. Results: A total of 56 articles were selected for review. Of the studies evaluated, 14 were randomized trials. All interventions except two targeted adult patients. Thirty-three studies enrolled fewer than 100 patients. Most interventions were education- and counseling-based and centered on provision of information about the drug and strategies to manage side effects. Only eight studies used an mHealth tool and/or text messages to target nonadherence. Among studies with a comparison sample, fewer than one-half (44.7%) reported statistically significant improvements in adherence or persistence associated with the intervention; however, some pharmacist-directed programs, particularly those that integrated monitoring or routine follow-up with a provider, did demonstrate efficacy. Conclusion: Although the development of adherence-promoting interventions for oral antineoplastic therapies has increased recently, few have been rigorously tested. The nascent literature suggests those that are pharmacist directed and use regular monitoring show promise, though additional prospective studies are needed. Study methodology, population selection, and potential challenges that may be encountered in the implementation and dissemination phases should be considered when developing new interventions to address nonadherence to oral antineoplastic treatment.Keywords
Funding Information
- Breast Cancer Research Foundation to AHP
- Agency for Healthcare Research and Quality (K01HS023680)
This publication has 105 references indexed in Scilit:
- Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS studyBMC Cancer, 2013
- Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort studyBMJ Open, 2013
- The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerAnnals of Oncology, 2013
- A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancerBreast Cancer Research and Treatment, 2012
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerJournal of Clinical Oncology, 2012
- Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical careSupportive Care in Cancer, 2010
- Cancer treatment adherence among low‐income women with breast or gynecologic cancerCancer, 2009
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008